Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity

Eli Lilly (LLY) PT Raised to $1,050 at Jefferies

August 2, 2024 7:06 AM EDT

Jefferies analyst Akash Tewari raised the price target on Eli Lilly (NYSE: LLY) to $1,050.00 (from $1,041.00) while maintaining a Buy rating.

... More